Johnson & Johnson (NYSE:JNJ) Position Decreased by Deutsche Bank AG

Deutsche Bank AG lowered its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,330,124 shares of the company’s stock after selling 59,934 shares during the period. Johnson & Johnson makes up 1.5% of Deutsche Bank AG’s investment portfolio, making the stock its 5th largest position. Deutsche Bank AG owned about 0.58% of Johnson & Johnson worth $2,721,251,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after purchasing an additional 3,358,478 shares during the last quarter. BlackRock Inc. grew its position in Johnson & Johnson by 0.4% during the 1st quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after acquiring an additional 777,837 shares during the last quarter. Wellington Management Group LLP grew its position in Johnson & Johnson by 0.8% during the 1st quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after acquiring an additional 265,330 shares during the last quarter. Bank of New York Mellon Corp grew its position in Johnson & Johnson by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock worth $5,683,837,000 after acquiring an additional 509,818 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Johnson & Johnson by 1.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after acquiring an additional 328,297 shares during the last quarter. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

JNJ opened at $177.01 on Thursday. The stock has a market cap of $462.79 billion, a PE ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The business has a 50 day moving average of $168.35 and a 200-day moving average of $171.28. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.60 EPS. Equities research analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has initiated a stock buyback program on Wednesday, September 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s payout ratio is presently 62.95%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the transaction, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the transaction, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold a total of 212,646 shares of company stock worth $36,791,022 in the last quarter. 0.35% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on JNJ. Morgan Stanley reduced their price target on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 19th. Barclays initiated coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Atlantic Securities cut their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Credit Suisse Group initiated coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective on the stock. Finally, Raymond James cut their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.